Search details
1.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37964482
2.
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).
J Urol
; 209(6): 1082-1090, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37096583
3.
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
Qual Life Res
; 32(11): 3209-3221, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37410340
4.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Lancet Oncol
; 23(7): 899-909, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35690072
5.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate
; 82(12): 1176-1185, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35538398
6.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
J Urol
; 205(1): 22-29, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32960678
7.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
J Urol
; 205(1): 14-21, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-32960679
8.
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.
Nature
; 523(7560): 347-51, 2015 Jul 16.
Article
in English
| MEDLINE | ID: mdl-26030522
9.
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
J Urol
; 204(6): 1173-1179, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32552295
10.
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Prostate
; 79(6): 604-613, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30663074
11.
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Invest New Drugs
; 37(2): 331-337, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30402678
12.
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.
Invest New Drugs
; 37(6): 1231-1238, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31231785
13.
Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer.
Invest New Drugs
; 37(3): 559-566, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31037562
14.
Renal cell carcinoma for the nephrologist.
Kidney Int
; 94(3): 471-483, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29661544
15.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Article
in English
| MEDLINE | ID: mdl-27939400
16.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 373(8): 737-46, 2015 Aug 20.
Article
in English
| MEDLINE | ID: mdl-26244877
17.
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.
Invest New Drugs
; 36(6): 1085-1092, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30191523
18.
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Invest New Drugs
; 36(3): 451-457, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29476383
19.
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Invest New Drugs
; 36(5): 919-926, 2018 10.
Article
in English
| MEDLINE | ID: mdl-30083962
20.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet
; 387(10031): 1909-20, 2016 May 07.
Article
in English
| MEDLINE | ID: mdl-26952546